RTI-229: Difference between revisions
CSV import |
CSV import |
||
| Line 27: | Line 27: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Phenyltropane 28a.svg|RTI-229 | |||
</gallery> | |||
Latest revision as of 01:15, 20 February 2025
RTI-229 is a tropane derivative drug that acts as a dopamine reuptake inhibitor and has been researched for use in treating cocaine addiction. It is a potent and selective DAT inhibitor, with a Ki of 0.16 nM, and is around 5x more potent than cocaine at inhibiting dopamine reuptake, although it produces significantly less locomotor stimulation in animals. It is named after the Research Triangle Institute (RTI), and is part of the phenyltropane group of compounds.
Pharmacology[edit]
RTI-229 is a phenyltropane based, highly potent and selective DAT inhibitor. It is around 5x more potent than cocaine at inhibiting dopamine reuptake. However, it produces significantly less locomotor stimulation in animals, which suggests a lower potential for recreational use.
Potential Medical Uses[edit]
RTI-229 has been researched for use in treating cocaine addiction. The drug's high potency and selectivity for the DAT over other targets make it a promising candidate for this application. However, further research is needed to fully understand its potential benefits and risks.
